Merck KGaA, Darmstadt, Germany in the news

MilliporeSigma's SPARK program marked its 10th anniversary by engaging thousands of employees in STEM education and community outreach, reaching over 60,000 students globally in the first half of 2026 through initiatives like the Curiosity Cube and Curiosity Labs.

Merck KGaA is projected to reach approximately 62,759 employees globally by March 2026, marking a 2.8% growth from its 2023 headcount of 61,061.

Cyllene Therapeutics secured €33 million in Series C funding to advance its lead DNA medicine candidate, EG110A, and expand its HERMES platform.

Merck KGaA will acquire Bio-Techne Corp. for $11.3 billion to expand its life sciences capabilities in high-growth areas.

Merck KGaA is acquiring Bio-Techne for $11.3 billion to enhance its life science portfolio in high-growth areas and strengthen its position as a supplier of essential lab materials.

Merck is acquiring Bio-Techne for $11.3 billion at $73 per share.

Merck KGaA, Darmstadt, Germany is acquiring Bio-Techne, a Minneapolis life sciences firm with 500,000 products, for $11.3 billion to expand its offerings in drug development and manufacturing.

Merck KGaA, Darmstadt, Germany, is set to acquire Bio-Techne Corporation for $11.3 billion in an all-cash deal.

Merck KGaA is acquiring Bio-Techne Corporation, a global provider of life science tools, for approximately US$11.3 billion.

Merck KGaA is acquiring Bio-Techne Corporation, a global provider of life science tools, for approximately US$11.3 billion.

Merck KGaA, Darmstadt, Germany partnered with Versant Ventures to launch Saturnus Bio, investing $50 million and securing an option to acquire the precision cardiology company.

Merck KGaA, Darmstadt, Germany entered a strategic research collaboration with Saturnus Bio, a Versant Ventures-founded biotech, to advance treatments for rare genetic cardiomyopathies with an upfront payment of $50 million and an acquisition option.

Merck KGaA, Darmstadt, Germany collaborated with Versant Ventures to launch Saturnus Bio, advancing treatments for rare genetic cardiomyopathies with a $50 million upfront investment and an exclusive acquisition option.

Merck KGaA, Darmstadt, Germany, has globally adopted Veeva Vault CRM to enhance its commercial foundation, integrating agentic AI and industry-specific capabilities into its digital initiatives.

Merck KGaA has dosed the first patient in its Phase 3 trial of precemtabart tocentecan, an antibody-drug conjugate targeting metastatic colorectal cancer.

Merck KGaA holds significant rankings in Germany, including 45th among top companies, 14th among largest family businesses, and is a recognized world market leader in life science and performance materials.

Helene Garijo, previously CEO of Merck's Healthcare division, is appointed as the new CEO of Sanofi.

Merck's current and future leadership are addressing concerns about the European production landscape and the modernized Darmstadt site.

Merck KGaA, Darmstadt, Germany launched a high-performance computer hosted by Equinix and powered by Lenovo to advance AI innovation and scientific discovery across its business sectors.

Merck secures tariff exemptions with the US government in exchange for lowering the cost of several fertility medications and investing in US biopharmaceutical production.